After Today’s Significant Decline, Is Myriad Genetics, Inc. (MYGN)’s Near-Term Analysis Negative?

Myriad Genetics, Inc. (NASDAQ:MYGN) Logo

Investors sentiment decreased to 1.05 in 2019 Q1. Its down 0.18, from 1.23 in 2018Q4. It dropped, as 34 investors sold Myriad Genetics, Inc. shares while 69 reduced holdings. 38 funds opened positions while 70 raised stakes. 76.62 million shares or 2.98% more from 74.41 million shares in 2018Q4 were reported.
Alliancebernstein L P has 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Hall Laurie J Trustee owns 160 shares. Tekla Capital Mngmt Limited Liability Company owns 20,549 shares or 0.03% of their US portfolio. Advisory Svcs Networks Ltd reported 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Assetmark reported 0% stake. Pictet Asset Management invested 0.02% in Myriad Genetics, Inc. (NASDAQ:MYGN). Birchview Capital Limited Partnership holds 20,000 shares or 0.42% of its portfolio. Louisiana State Employees Retirement stated it has 0.05% in Myriad Genetics, Inc. (NASDAQ:MYGN). Arizona State Retirement Sys has invested 0.04% in Myriad Genetics, Inc. (NASDAQ:MYGN). Baillie Gifford has 0.35% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Bamco Ny holds 509,564 shares or 0.07% of its portfolio. Dekabank Deutsche Girozentrale invested 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). South Dakota Council has invested 0.01% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). 30,500 were reported by Strs Ohio. Robecosam Ag invested in 15,120 shares or 0.02% of the stock.

The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) is a huge mover today! The stock decreased 38.96% or $17.35 during the last trading session, reaching $27.19. About 8.44 million shares traded or 599.84% up from the average. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 31.84% since August 14, 2018 and is downtrending. It has underperformed by 31.84% the S&P500.
The move comes after 5 months negative chart setup for the $2.00B company. It was reported on Aug, 14 by We have $25.83 PT which if reached, will make NASDAQ:MYGN worth $99.75 million less.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on August, 20. They expect $0.40 earnings per share, up 5.26 % or $0.02 from last year’s $0.38 per share. MYGN’s profit will be $29.35M for 16.99 P/E if the $0.40 EPS becomes a reality. After $0.34 actual earnings per share reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts 17.65 % EPS growth.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

Among 2 analysts covering Myriad Genetics (NASDAQ:MYGN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Myriad Genetics had 11 analyst reports since March 6, 2019 according to SRatingsIntel. On Tuesday, March 12 the stock rating was maintained by Needham with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Thursday, March 14 report. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Hold” rating by Deutsche Bank on Monday, August 5.

More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: which released: “Microcaps mostly among midday movers – Seeking Alpha” on August 14, 2019, also with their article: “Myriad’s myPath® Melanoma Test Receives Medicare Coverage – GlobeNewswire” published on March 14, 2019, published: “Myriad Genetics Inc (MYGN) Q4 2019 Earnings Call Transcript – Yahoo Finance” on August 14, 2019. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: and their article: “Here’s What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) – Yahoo Finance” published on April 29, 2019 as well as‘s news article titled: “Mid-Day Market Update: Crude Oil Down Over 5%; Purple Innovation Shares Rises After Q2 Results – Benzinga” with publication date: August 14, 2019.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.00 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 453.25 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.